cyrilzakka/clinical-trials huggingface dataset:
Uterocervical Angle Versus Cervical Length as a Predictor of Labor Induction in Term Singleton Pregnancy

Induction of labor is frequently performed in all obstetric clinics. Failed IOL has been defined in many different ways.Bishop scoring, which is a traditional and subjective method, is more frequently evaluated with cervical length, which has taken its place in preterm labor, and various ultrasonographic evaluations such as Uterocervical angle (UCA), Posterior cervical angle (PCA), cervical elastography, transvulvar ultrasonography, which have recently increased in popularity, have gained importance and led us to evaluate these parameters in our clinic. The relationship between the angles between the uterus and cervix and labor has been known for some time.

Induction of labor is frequently performed in all obstetric clinics for various indications, with a worldwide spectrum ranging from 1.4 to 35%. Failed IOL has been defined in many different ways. It has been defined as a dilatation of less than 4 cm despite administration of oxytocin for 12 hours±3 hours (target 200-225 MVU or 3 contractions/10 min), induction of labor with oxytocin for at least 12-18 hours (after rupture of membranes) and a latent phase lasting 24 hours or longer, primarily considering fetal and maternal well-being. In some sources, it is defined as failure to achieve regular (e.g. every 3 minutes) uterine contractions and cervical changes with artificial rupture of membranes after at least 6-8 hours of oxytocin maintenance dose. For this reason, various subjective \& ultrasonographic parameters used to predict induction success are of great importance for the evaluation of the cervix. Bishop scoring, which is a traditional and subjective method, is more frequently evaluated with cervical length, which has taken its place in preterm labor, and various ultrasonographic evaluations such as Uterocervical angle (UCA), Posterior cervical angle (PCA), cervical elastography, transvulvar ultrasonography, which have recently increased in popularity, have gained importance and led us to evaluate these parameters in our clinic.

The relationship between the angles between the uterus and cervix and labor has been known for some time.

Eligibility Criteria:
Inclusion Criteria:

37 weeks and older Nulliparity Live, singular Verteks presentation Cervical opening\<3 cm Bishop score\<7 Patients not in active action

Exclusion Criteria:

* Presence of contraindications to vaginal delivery (pls previa, detached pls...)
* History of previous uterine surgery
* Multiple pregnancies
* Non-vertex presentation
* Uncontrolled HT Uncontrolled DM
* Fetal distress
* Macrosomic fetus Patients in active labor
Epidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile

This is an observational study looking at the characteristics of patients consulting for genital warts in the first semester 2010 at the public sexual health clinic of Valparaiso, Chile. The objectives are: to have an epidemiological profile, estimating cost of the disease for the health system and the patient and analyzing possible psychosocial consequences of the condition for the patients.


Eligibility Criteria:
Inclusion Criteria:

* Men and women 18 years of age or older
* Having being diagnosed with genital warts
* Consulting the sexual health clinic only for genital warts
* Patients accepting to be included in the study

Exclusion Criteria:

* Immunodeficiency
* HIV positive
* Having being diagnosed with cancer or pre-cancerous lesions
* Pregnancy
* Presenting a sexual transmissible infection other than genital warts.
Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

This is a longitudinal, consecutive case-series, multi-center study with mixed prospective and retrospective data collection. Data will be collected from eligible adults with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) treated with dacomitinib as first-line therapy from the date of advanced NSCLC diagnosis to the date of death, lost to follow-up, withdrawal of consent or end of study, whichever occurs first.


Eligibility Criteria:
Inclusion Criteria:

* Adult (aged ≥18 years) with histology-confirmed advanced NSCLC (TNM stage IIIB-IV);
* Presence of any EGFR-activating mutation (exon 19 deletion or exon 21 L858R substitution) or other uncommon EGFR mutations prior to anti-cancer treatment;
* Initiating dacomitinib as first-line treatment after confirmation of EGFR-mutation status (ie, no prior treatment with other EGFR TKI or systemic therapy);

Exclusion Criteria:

* Enrolled in any interventional clinical study or trial (however, patients enrolled in non-interventional, real world study may still be included).
Adrenal Insufficiency in Septic Shock

Randomized controlled trial evaluating the duration of steroid replacement therapy in patients with adrenal insufficiency and septic shock. Patients will be randomized to receive either hydrocortisone 50 mg IV every six hours for seven days (control) or hydrocortisone 50 mg IV every six hours until 24 hours after achievement of hemodynamic stability (MAP \> 65 mm Hg off of vasopressors).


Eligibility Criteria:
Inclusion Criteria:

* Patients who are 18 years of age or older
* Patients who sign informed consent or are represented by a legally authorized representative to provide consent on behalf of the patient
* Patients with septic shock meeting the ACCM/SCCM consensus conference definitions for septic shock

Exclusion Criteria:

* Patients with documented allergic or anaphylactic reactions to corticosteroids
* Patients who have received steroid therapy within 6 months of presentation
* Patients who have received steroids during their hospital admission, with the exception of a single dose of dexamethasone
* Patients who have received etomidate in the preceding 12 hours
* Patients who have had a prior adrenalectomy or a known history of adrenal disease (documented adrenal insufficiency or Cushing syndrome).
* Documented Human Immunodeficiency Virus (HIV) infection
* Pregnancy
* Allergies to adrenocorticotropic hormone (ACTH) or corticosteroids
* Administration of additional medications which may suppress the hypothalamic-pituitary axis:

  * Ketoconazole
  * Aminoglutethimide
  * Mitotane
  * Megestrol acetate
  * Suramin
Diagnostic Value of Arterial Blood Gas Analysis in Prehospital Patients

In the anesthesiologist-manned mobile emergency car unit an analyzing device for blood gas testing is present since 2014. This study will determine if a prehospital arterial blood gas helps the doctor to make more precise diagnosis prehospitally. Furthermore it will be determined if the doctors find this device helpful in assessing and treating patients with affected consciousness.


Eligibility Criteria:
Inclusion Criteria:

* GCS \< 13

Exclusion Criteria:

* Pregnant or breastfeeding
* detained or imprisoned patient
Physical Activity and Nutrition Intervention in Afterschool Programs

The investigators long-term goal is to advance the adoption and successful implementation of policies that promote PA and nutrition in after school programs (ASP) nationwide. The investigators objective here is two fold. First, the investigators will test the effectiveness of two promising strategies designed to 1) increase the amount of PA children accumulate while attending an ASP and 2) promote changes in the nutritional quality of the snacks served. This represents a fundamental step in establishing practice-based guidelines (best practices) for the uptake and achievement of public health policy goals (CA and Harvard). Second, the investigators will examine the barriers and facilitators to implementing these strategies. The expected outcome of this study is evidence supporting best practices for ASPs to employ to meet policy goals.

The investigators will use a 3-year delayed treatment, cluster randomized controlled trial design with 20 ASPs that serve mostly low-income and minority children (approximately 1300 children ages 6-12yrs) in Columbia, SC and address the following specific aims: Aim 1. Evaluate the impact of a staff-level intervention, a professional development training program focused on core competencies to promote physical activity, on children's physical activity levels; Aim 2. Evaluate the impact of a site-level intervention, a snack modification program that includes a discount buying program, on the quality of snacks served and consumed; and Aim 3. Evaluate the implementation of the staff-level and site-level interventions and identify organizational, staff, and setting characteristics that influence the process of implementing these strategies.

Eligibility Criteria:
Inclusion Criteria:

Programs that:

* Operate immediately after the school day
* Operate every day of the school year for a minimum of 2 hours
* Serve a minimum of 30 children of elementary age (6-12 years)
* Operate in a school, community or faith Setting
* Provide a snack
* Provide homework assistance/completion time
* Provide enrichment
* Provide opportunities for physical activity
* All children enrolled, staff, and afterschool program (ASP) leaders in the ASPs were eligible to participate in the study.

Exclusion Criteria:

* Programs that:
* Were singularly focused
* Programs that were physical activity focused

Children that:

* Have any physical and/or orthopedic impairment that would limit a child's ability to participate in regular physical activity.
A Clinical Study of the Effects of Environmental Pollution on Obesity

This study aims to assess the effects of environmental pollution (including environmental indicators such as PM2.5, PM5, PM10, SO2, NOX, O3, and greening index) on obese patients and to explore the possible mechanisms by which environmental pollution promotes obesity.

Firstly, the effects of environmental pollution on obese patients were investigated by analysing the baseline conditions and obesity levels (including BMI, waist circumference, hip circumference, etc.) and underlying diseases of obese patients in regions with different pollution levels. Secondly, the association between environmental pollution levels on blood test characteristics (including renal function, sex hormones, glucose tolerance test, trace elements, liver function and blood routine) of obese patients was investigated to find possible mechanisms.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years;
* obese patients with BMI ≥30;
* patients without surgical treatment prior to enrolment;
* willingness to participate in the study and sign an informed consent form;
* complete clinical data.

Exclusion Criteria:

* patients with systemic diseases such as severe cardiorespiratory insufficiency affecting the choice of treatment regimen;
* patients assessed by the investigator to be inappropriate for enrolment;
* patients with incomplete clinical data.
Autologous Adipose Tissue Derived Mesenchymal Stem Cells for Rotator Cuff Disease

The purpose of this study is to evaluate safety and efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells injection in patient with Rotator Cuff disease.


Eligibility Criteria:
Participants should meet all the inclusion criteria. Patients must consent in writing to participate in the study by signing and dating an informed consent document approved by IRB indicating that the patient has been informed of all pertinent aspects of the study prior to completing any of the screening procedures

Inclusion Criteria:

1. Male or female 19 years of age and older.
2. Patients who have unilateral shoulder pain.
3. Patients who have had pain at least for 3 months and do not respond to conservative treatment.
4. Patients who have a partial-thickness rotator cuff tear confirmed with magnetic resonance imaging (MRI) or ultrasonography (US).

Exclusion Criteria:

Participants who met a single condition were excluded from the study

1. Patients who received any drug by subacromial injection for treatment within 3 months prior to this enrollment.
2. Patients who have a history of shoulder trauma including dislocation, subluxation, and fracture, breast cancer, or surgery around shoulder, neck and upper back within 6 months prior to this enrollment.
3. Patients who have a full-thickness rotator cuff tear
4. Patients who have radiological findings of malignancy, osteoarthritis of the glenohumeral joint, and skeletal abnormalities decreasing the subacromial space
5. Patients with symptomatic cervical spine disorders
6. Patients with concurrent bilateral shoulder pain
7. Patients with adhesive capsulitis, acromioclavicular arthropathy, polyarthritis, infectious arthritis, rheumatoid arthritis or diagnosed fibromyalgia
8. Patients with neurological deficit
9. Pregnant women or lactating mothers
10. Fertile woman of childbearing potential not willing to use adequate contraception for the study duration
11. Patients taking anticoagulants
12. Patients who are positive serology for human immunodeficiency (HIV), hepatitis B (HBV) or hepatitis C (HCV) and syphilis
13. Patients with serious condition which can affect this study such as severe cardiovascular diseases, renal diseases, liver diseases, endocrine diseases, and cancers
14. Patients who are difficulty participating in data collection due to communication problem and serious mental illness
15. Patients are unable to come into the clinic for regular follow-up
16. Patients who had participated in other clinical trials within 3 months prior to this study.
17. Patients who the principal investigator considered inappropriate for the clinical trial due to any other reasons than those listed above.
FMRI Assessment After Radiofrequency in Trigeminal Neuralgia

To investigate the brain activations related to TN, using fMRI, and to evaluate changes in these activations following the application of pulsed and thermal Radiofrequency lesioning to the gasserien ganglion.


Eligibility Criteria:
Inclusion Criteria:

* Age 20 - 65 years
* Primary trigeminal neuralgia
* Maxillary and/or mandibular affection only
* Failure of medical treatment

Exclusion Criteria:

* 2ry trigeminal neuralgia
* Recurrent trigeminal neuralgia
* Ophthalmic branch affection
* Contraindication for intervention (sepsis, coagulopathy, infection at entery point, local anesthetic allergy,...)
* Pregnancy
Feasibility of WB-EMS in Frail Older People

Exercise in general and resistance training (RT) in particular have demonstrated positive effects on physical functioning and frailty. However, frail older people with functional impairments are among the least physically active and may have problems reaching high intensity levels. The use of special vests with integrated electrodes allows the simultaneous innervation of all large muscle groups by external electrical stimulation, inducing a high-intensity RT at low subjective effort level. This whole-body electromyostimulation (WB-EMS) may be a feasible option inducing training stimuli for functionally impaired frail older people.

This study aims at investigating the feasibility and safety of WB-EMS in frail older people with functional limitations. To explore the effects of age and functional status, young and robust old reference groups will serve as comparators.


Eligibility Criteria:
Frail people

Inclusion Criteria:

* 75+ years
* Frail
* able to walk 4m w/o walking aid
* no prior WB-EMS exposure

Exclusion Criteria:

* severe visual or hearing impairments
* major cognitive impairment (MMSE \<10)
* medications with muscle-anabolic effects
* medical conditions affecting trainability of muscles (e.g. Myasthenia gravis, Cushing syndrome, Morbus McArdle)
* surgery within past two months
* history of rhabdomyolysis
* medical conditions affecting sensation of electrical stimuli (e.g. severe polyneuropathy)
* severe renal insufficiency (eGFR\<30 ml/min/1.73m²)
* electronic implants
* acute or untreated abdominal wall or inguinal hernia

Robust people

Inclusion Criteria:

* 75+ years
* Robust
* no prior WB-EMS exposure

Exclusion Criteria:

* severe visual or hearing impairments
* major cognitive impairment (MMSE \<10)
* medications with muscle-anabolic effects
* medical conditions affecting trainability of muscles (e.g. Myasthenia gravis, Cushing syndrome, Morbus McArdle)
* surgery within past two months
* history of rhabdomyolysis
* medical conditions affecting sensation of electrical stimuli (e.g. severe polyneuropathy)
* severe renal insufficiency (eGFR\<30 ml/min/1.73m²)
* electronic implants
* acute or untreated abdominal wall or inguinal hernia

Younger people

Inclusion Criteria:

* 18-50 years
* Healthy
* no prior WB-EMS exposure

Exclusion Criteria:

* severe visual or hearing impairments
* major cognitive impairment (MMSE \<10)
* medications with muscle-anabolic effects
* medical conditions affecting trainability of muscles (e.g. Myasthenia gravis, Cushing syndrome, Morbus McArdle)
* surgery within past two months
* history of rhabdomyolysis
* medical conditions affecting sensation of electrical stimuli (e.g. severe polyneuropathy)
* severe renal insufficiency (eGFR\<30 ml/min/1.73m²)
* electronic implants
* acute or untreated abdominal wall or inguinal hernia
* pregnancy
ERILs Und SNILs Unter SOC

1. How many ERILs occur in caucasian patients with LAA stroke during 7 days on standard treatment?
2. How many SNILs occur between 7 and 30 days after acute ischemic event on standard treatment?
3. How many of during acute event diagnosed lesions (ERILs) are (still) detectable after 30 days?
4. Are there relevant risk faktors for the occurence of ERILs and SNILs (eg Diabetes or Biomarkers)?

In this trial, patients will be observed if they develop early recurrent ischemic lesions (= ERILs) or silent neurologic ischemic lesions (= SNILs) after acute stroke or transitoric ischemic attack (TIA) based on atherothrombosis (LAA-stroke) on standard therapy during 30 days (day 7 and day 30 after acute event) via DW-MRI (diffusion-weighted magnetic resonance imaging).

We want to investigate if diffusion-weighted imaging of silent brain infarcts occuring during standard therapy is a suitable surrogate outcome measure for interventional studies

Eligibility Criteria:
Inclusion Criteria:

* LAA stroke or TIA
* ERILs or SNILs detected in initialDW-MRI
* signed informed consent

Exclusion Criteria:

* planned surgical intervention
* iv Thrombolysis
* atrial fibrillation
* contra indications against DW-MRI
Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.

The objective of the current study is to investigate safety, tolerability, and pharmacokinetics of treatment with BI 661051 rising single doses administered as oral drinking solution (powder in bottle) in healthy male subjects.

The primary objective is to investigate the safety and tolerability of treatment with BI 661051.

The secondary objectives are (1) to evaluate the single dose pharmacokinetics of BI 661051, (2) to explore dose proportionality, (3) to explore the relative bioavailability when BI 661051 is administered as tablet at two dose levels compared to oral drinking solution and (4) to assess the effect on the bioavailability when BI 661051 is administered as oral drinking solution after intake of a high fat meal.

Pharmacodynamic parameters will not be determined within this study.

Purpose:

Eligibility Criteria:
Inclusion criteria:

1. Healthy males based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests. There is no finding deviating from normal and of clinical relevance. There is no evidence of a clinically relevant concomitant disease.
2. Age =18 and age =50 years.
3. BMI =18.5 and BMI =30 kg/m2 (Body Mass Index).
4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation.

Exclusion criteria:

1. Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance.
2. Any evidence of a clinically relevant concomitant disease.
3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.
5. History of relevant orthostatic hypotension, fainting spells or blackouts.
6. Chronic or relevant acute infections.
7. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) as judged clinically relevant by the investigator.
8. Intake of drugs with a long half-life (\>24 h) within at least 1 month or less than 10 half-lives of the respective drug prior to administration.
9. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to randomisation.
10. Participation in another trial with an investigational drug within 30 days prior to randomisation.
11. Smoker (\>10 cigarettes or \>3 cigars or \>3 pipes/day).
12. Inability to refrain from smoking on trial days as judged by the investigator.
13. Alcohol abuse (more than 30 g/day).
14. Drug abuse.
15. Blood donation (more than 100 mL within 4 weeks prior to randomisation or during the trial).
16. Excessive physical activities (within 1 week prior to randomisation or during the trial).
17. Any laboratory value outside the reference range that is of clinical relevance.
18. Inability to comply with dietary regimen of the study centre.
Post-operative Hernias After Radical Cystectomy

Post-operative hernias after cystectomy are frequent (our review of the literature with meta-analysis found an incidence of evisceration at 5%, median eventrations at 8% and peristomal hernias at 14%). These represent a non-negligible and partially morbidity. avoidable, subject to proper assessment of personal and surgical risk factors


Eligibility Criteria:
Inclusion criteria:

* having undergone a cystectomy (for cancer or not),
* with or without reconstruction, between 01/01/2010 and 12/31/2020

Exclusion criteria:

- refusing to participate